Clinical Trial Update: A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating SAGE-324 for essential tremor was terminated; results have been posted as of 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Tremor

Drugs mentioned

• SAGE-324 (SAGE-324)

Snippet

Sponsor: Sage Therapeutics | Conditions: Essential Tremor | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2025-08-01